Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background Intact corneal epithelium is important for the defense on the ocular surface, and the function of limbal stem cells is crucial to maintain its integrity. Certain chronic eye diseases, such as glaucoma, require long-term medication use. However, glaucoma patients often exhibit corneal punctate erosions and ocular surface inflammation. In cases where medication has been used for an extended period, patients may even show symptoms similar to limbal stem cell deficiency. Understanding how glaucoma medications affect the function of corneal limbal stem cells is a critical clinical issue. Objectives To evaluate the effect of glaucoma and anti-glaucoma agents on corneal epithelial and limbal epithelial thickness as a surrogate of limbal stem cell function, and to understand the association between tear fluid proteome and limbal function in glaucoma patients. Methods We planned to include 90 subjects with glaucoma, and analyze the absolute thickness and variation of corneal epithelium and limbal epithelium. Tear fluid samples will be collected and proteomic analysis will be performed to elucidate the association between protein. Anticipated Results To elucidate the impact of different types and cumulative doses of glaucoma medications on the thickness of the corneal epithelium and limbal epithelium, and to understand the relationship between limbal function and tear proteomics in glaucoma patients. The expected results may help develop early detection methods for changes in corneal and limbal epithelial function and provide valuable insights for future research on drug design and the protection of limbal stem cells.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• i. Age ≥ 18 years. ii. Healthy Control Group: No diagnosis of glaucoma or ocular hypertension. iii. Glaucoma, Newly Diagnosed Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; antiglaucoma medication usage for less than 3 months.

• iv. Glaucoma, Long-term Medication Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; continuous use of intraocular pressure-lowering medications for more than 1 year.

• v. Glaucoma, Unilateral Group: Diagnosed with unilateral glaucoma or ocular hypertension; only one eye receiving intraocular pressure-lowering treatment.

Locations
Other Locations
Taiwan
National Taiwan University Hospital Hsinchu Branch
RECRUITING
Hsinchu
Contact Information
Primary
Wei-Lun Huang, MD
weilunhuang@ntu.edu.tw
886-3-6677600
Time Frame
Start Date: 2025-07-08
Estimated Completion Date: 2026-12
Participants
Target number of participants: 90
Treatments
Healthy control
Healthy control, without diagnosis of glaucoma.
Glaucoma, newly diagnosed
Glaucoma patients who received topical antiglaucoma medications for less than 3 months.
Glaucoma, long-term medication use
Glaucoma patients, received topical antiglaucoma medications for 1 year or longer.
Glaucoma, unilateral
Patients with unilateral glaucoma or ocular hypertension and received treatment only in the diseased eye.
Sponsors
Leads: National Taiwan University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials